Search Patents
  • Medicine for Covid-19 and treatment
    Patent number: 11278602
    Abstract: The invention concerns a medicine and a prophylactic medicine for COVID-19 disease. The inventive medicine targets the endosomic, non-endosomic and/or intracellular viral pathways and inhibits them. The best mode of the invention is considered to be the medicine that blocks all three viral pathways. In the best mode the individual dose of a constituent component of the medicine is arranged to a dosage size sufficient to inhibit its designated SARS-CoV-2 viral pathway. This allows the dose of a particular pharmacological agent to be smaller than in a drug with just one kind of pharmacological agent. The best mode of the invention shuts the two cell membrane viral pathways and the one intracellular viral pathway with the minimum efficient dose, thereby preventing drug overdose, and enabling prophylactic or preventive use.
    Type: Grant
    Filed: March 22, 2021
    Date of Patent: March 22, 2022
    Assignee: THERAPEUTICA BOREALIS OY
    Inventors: Kalervo Väänänen, Lauri Kangas, Matti Rihko
  • Lateral flow immunoassay test reader and method of use
    Patent number: 10823746
    Abstract: A reader for a lateral flow test device includes a tray or drawer, extendable from the reader, which receives the test device. The tray includes a calibration test pattern affixed or printed thereon placed proximate to the test device and in alignment with the axis of the test device. As the tray is closed and the test device is inserted to the reader, the calibration test pattern is first read by an optics unit including a photodiode. The resulting photodiode output provides a calibration curve S that the reader then uses to correct for any non-linear response of the reader's optical or electronic systems, thus insuring that every reader will yield the same readout for a given test cartridge, despite reader-to-reader variations or reader degradation with time. One use of the reader is for detection of SARS-CoV-2 infection.
    Type: Grant
    Filed: May 28, 2020
    Date of Patent: November 3, 2020
    Assignee: Thermogenesis Holdings, Inc.
    Inventors: William Busa, Phillip H. Coelho, Paul Getchel
  • DEVICE FOR ACUPUNCTURE AND MOXIBUSTION THERAPY AND USES THEREOF
    Publication number: 20240041697
    Abstract: The present invention provides an acumoxa therapy device utilizing energy waves for preventing, alleviating or treating COVID-19 (SARS-CoV-2) coronavirus infection. In one embodiment, the device delivers energy in a non-invasive manner. In one embodiment, the device is configured to include an energy pin and one or more energy rings. In one embodiment, the device delivers sufficient energy to certain body parts such as acupoints to achieve an intervening and/or therapeutic effect. In one embodiment, the device can maintain or improve general health, or can alleviate or treat a subject with COVID-19 infection and one or more other conditions. In one embodiment, the present invention also discloses a system comprising the device and uses thereof.
    Type: Application
    Filed: October 13, 2023
    Publication date: February 8, 2024
    Inventor: Xunhua ZHANG
  • NOVEL REOVIRUS-BASED VACCINE PLATFORM AND USE THEREOF
    Publication number: 20250154204
    Abstract: The present invention relates to a novel reovirus-based vaccine platform, and confirmed that a part of the S1 gene of reovirus can be replaced with various exogenous epitope-encoding genes, and a recombinant reovirus manufactured according to the present invention not only can infect target cells and induce the expression of the epitope, but also can effectively prevent and treat diseases related to the epitope by activating the immune function of immune cells against the epitope. When using the reovirus-based vaccine platform of the present invention, vaccines containing various epitopes can be manufactured through relatively simple genetic manipulation technology, and can be administered in various ways including oral administration, so it can be utilized for the prevention and treatment of various infectious diseases including SARS-CoV-2 virus infection, and cancer.
    Type: Application
    Filed: September 26, 2022
    Publication date: May 15, 2025
    Inventors: Haeng Jun YOO, Tommy Michel ALAIN, Sang Kyoung HAN, Yeon Sook LEE, Xiao XIANG
  • Method for maximizing coronavirus killing activity of high-density lipoproteins, and pharmaceutical composition for preventing or treating COVID-19
    Patent number: 12274715
    Abstract: The present invention relates a method for maximizing the coronavirus killing activity of high-density lipoproteins, and a pharmaceutical composition for preventing or treating COVID-19. As identified by the present inventors, non-glycated normal high-density lipoproteins (HDLs) exhibit killing activity against coronavirus (SARS-Cov-2) that is superior to that of glycated HDLs, and thus a pharmaceutical composition for preventing and treating COVID-19, containing non-glycated native HDLs as an active ingredient, is provided. In addition, the present invention is useful since a method for maximizing the coronavirus killing activity by using an HDL glycation inhibitor, on the basis of the identification by the present inventors, can be provided and a method for screening for a pharmaceutical composition for preventing and treating COVID-19 by evaluating the degree of HDL glycosylation inhibition of candidate drugs can be provided.
    Type: Grant
    Filed: December 22, 2021
    Date of Patent: April 15, 2025
    Assignee: Raydel Korea Co., Ltd.
    Inventor: Kyung-Hyun Cho
  • EQUIPMENT FOR DESTRUCTION OF CORONAVIRUSES BY MEANS OF COMPLEMENTARY RADIATION
    Publication number: 20230201626
    Abstract: The equipment for the destruction of viruses by means of complementary radiation consists of a technology focused on weakening the fatty layer covering certain viruses, to cause the indirect destruction of them. This technology utilizes intense, modulated light radiation, the principal emitters thereof being 460-nanometers LEDs which, with the technology of the invention, emit secondary radiation in a band ranging from 400 to 460 nanometers, in order to achieve the weakening and destruction of the fatty layer that covers viruses such as SARS-CoV-2. This light radiation is complemented with ultrasound pulses that complete the destructive effect of the interior of the virus. For this purpose, technology involving emission by means of stratified quantum excitation is employed, which uses monochromatic light-emitting diodes to achieve very-high-intensity polychromatic emissions highly controllable regarding tissue penetration.
    Type: Application
    Filed: April 20, 2021
    Publication date: June 29, 2023
    Inventor: Herman DÍAZ ARIAS
  • Identification of inhibitor peptides to bind with N-terminal Spike (S) and nonstructural protein (NSP) sequences of SARS-COV2 B.1.617.2 Delta or Omicron variants alone and combination with drug(s) for targeted antiviral therapy
    Publication number: 20230250136
    Abstract: The identified peptide sequences form moderate to strong heterodimeric complexes with SARS-COV2 (B.1.617.2) virus Spike envelope proteins and a range of virus nonstructural protein sequences NSP1-14. These identified peptides are proposed to use in antiviral immunotherapy and supportive combination with chemical compound(s) for chemotherapy. The sequence ID of the identified peptides are, Seq1: ISD1, Seq2: ISD2, Seq3: ISD3, Seq4: ISD4, Seq5: ISD5, Seq6: ISD6, Seq7 Ip2, Seq8: Ip1, Seq9: Ip3, Seq10: Ip5, Seq11: Ip7, Seq12: Ip8, Seq13: Ip9, Seq14: SOI1, Seq15: SOI2, Seq16: SOI5, Seq17: SOI7, Seq18: SOI9, Seq19: SO10, Seq20: SO11.
    Type: Application
    Filed: May 4, 2022
    Publication date: August 10, 2023
    Inventor: Dr. Subhajit Dasgupta
  • Medicine for Covid-19 and treatment
    Patent number: 11638722
    Abstract: The invention concerns a medicine and a prophylactic medicine for COVID-19 disease. The inventive medicine targets the endosomic, non-endosomic and/or intracellular viral pathways and inhibits them. The best mode of the invention is considered to be the medicine that blocks all three viral pathways. In the best mode the individual dose of a constituent component of the medicine is arranged to a dosage size sufficient to inhibit its designated SARS-CoV-2 viral pathway. This allows the dose of a particular pharmacological agent to be smaller than in a drug with just one kind of pharmacological agent. The best mode of the invention shuts the two cell membrane viral pathways and the one intracellular viral pathway with the minimum efficient dose, thereby preventing drug overdose, and enabling prophylactic or preventive use.
    Type: Grant
    Filed: January 14, 2022
    Date of Patent: May 2, 2023
    Assignee: THERAPEUTICA BOREALIS OY C/O AVANCE ATTORNEYS LTD.
    Inventors: Kalervo Väänänen, Lauri Kangas, Matti Rihko
  • Method for monitoring COVID-19
    Publication number: 20210260580
    Abstract: A method of sampling and testing for SARS-COV-2 virus in nasal and nasopharyngeal fluid using a plurality of microfluidic channels with a plurality of integrated electrodes in the microfluidic channels to detect the virus. In one example embodiment, a plurality of antibodies are fixed on a surface of at least one electrode by positive dielectrophoresis that increases the sensitivity of detection. Viral antigens bind to the antibodies separating from the fluid thereby signally that the virus is present as evidenced by the detection of the antigens. Sampling by microfluidic channels is more comfortable to a patient because microfluidic channels are soft, flexible and narrow compared to swabs. Another example embodiment of a method using microfluidic channels for collecting tears or saliva to determine blood glucose levels using a smartphone that has been modified to incorporate external filters quantitate glucose levels is also described.
    Type: Application
    Filed: April 26, 2021
    Publication date: August 26, 2021
    Inventor: Dawn Bennett
  • Nutraceutical formulations to prevent, treat, and inhibit excess cytokines, SARS-CoV-2 spike proteins, and mRNA vaccine spike proteins
    Patent number: 12357667
    Abstract: Combinations of cannabinoids, vitamins, trace elements, bioactive components, bioflavonoid polyphenols, proteolytic enzymes, amino acids, and antioxidants which work independently and synergistically for the prevention, treatment, and inhibition of excess cytokines caused by the immune response to extreme viral and bacterial infections, including the inhibition of COVID-19, Rhinovirus and/or other virus spike proteins and mRNA vaccine spike proteins from attaching to body organ cells, penetrating cell membranes, and the replication of virus particles and spike proteins inside the cells. Inhibition of inflammation and prevention of long-term side effects, health issues (long-haulers), and disease caused by the SARS-CoV-2 and its variants, Rhinovirus, other viruses, bacteria, and mRNA vaccines are provided by the nutraceutical compositions. Specific combinations of these compounds work synergistically to increase the efficacy of the independent nutraceuticals in treatment.
    Type: Grant
    Filed: July 28, 2022
    Date of Patent: July 15, 2025
    Assignee: Pono Lifestyle, LLC
    Inventor: Mark A Fluga
  • Method for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity
    Patent number: 7569536
    Abstract: The present invention provides: (1) antiviral agents that act by reducing or inhibiting the activity of SR proteins, more specifically, (i) antiviral agents that act by enhancing dephosphorylation of SR proteins, and (ii) antiviral agents that act by inhibiting proteins that phosphorylate SR proteins; (2) antiviral agents that act by inhibiting the expression of SR proteins, and (3) antiviral agents that act by activating proteins that antagonize SR proteins. The present invention also provides compounds that inhibit SRPKs, which phosphorylate SR proteins. Such compounds inhibit the activity of SR proteins and have antiviral activities. Various new viruses including SARS have emerged, and thus the present invention provides long-lasting broad-spectrum antiviral agents applicable to new viruses.
    Type: Grant
    Filed: December 24, 2004
    Date of Patent: August 4, 2009
    Inventors: Masatoshi Hagiwara, Takeshi Fukuhara, Masaaki Suzuki, Takamitsu Hosoya
  • MEDICINE FOR COVID-19 AND TREATMENT
    Publication number: 20210299230
    Abstract: The invention concerns a medicine and a prophylactic medicine for COVID-19 disease. The inventive medicine targets the endosomic, non-endosomic and/or intracellular viral pathways and inhibits them. The best mode of the invention is considered to be the medicine that blocks all three viral pathways. In the best mode the individual dose of a constituent component of the medicine is arranged to a dosage size sufficient to inhibit its designated SARS-CoV-2 viral pathway. This allows the dose of a particular pharmacological agent to be smaller than in a drug with just one kind of pharmacological agent. The best mode of the invention shuts the two cell membrane viral pathways and the one intracellular viral pathway with the minimum efficient dose, thereby preventing drug overdose, and enabling prophylactic or preventive use.
    Type: Application
    Filed: March 22, 2021
    Publication date: September 30, 2021
    Inventors: Kalervo VÄÄNÄNEN, Lauri KANGAS, Matti RIHKO
  • ETHYNYLINDOLE COMPOUNDS
    Publication number: 20100160647
    Abstract: As a compound having a potent oral activity and a long-lasting cysLT1/cysLT2 receptor antagonistic activity, the compound of the formula (I): which exhibits potent antagonistic activity against the cysLT1/cysLT2 receptor, and have long-lasting effects even in case of oral administration, and therefore is useful as an oral agent for preventing and/or treating a variety of diseases, for example, respiratory disease (for example, asthma (bronchial asthma, etc.), chronic obstructive pulmonary disease (COPD), pulmonary emphysema, chronic bronchitis, pneumonia (interstitial pneumonia, etc.), severe acute respiratory syndrome (SARS), acute respiratory distress syndrome (ARDS), apnea syndrome, allergic rhinitis, sinusitis (acute sinusitis, chronic sinusitis, etc.), pulmonary fibrosis, coughing (chronic coughing, etc.), and the like) was developed.
    Type: Application
    Filed: December 22, 2009
    Publication date: June 24, 2010
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Kazuyuki OHMOTO, Satoshi ITADANI, Yoshisuke NAKAYAMA, Jun TAKEUCHI, Manabu FUJITA
  • COMPOSITIONS AND METHODS FOR PREVENTING AND/OR TREATING MICROBIAL INFECTIONS
    Publication number: 20230201244
    Abstract: Provided are methods for inhibiting immune responses against microbial antigens. In some embodiments, the methods include administering to the subject a composition containing a plurality of plant-derived exosome-like particles to inhibit immune esponses against microbial antigens. Also provided are methods for inhibiting development of septic shock in subjects, for inhibiting development of cytokine storm in subjects, and for inhibiting SARS-CoV-2-induced cytopathogenic effect. Also provided are compositions that include an exosome-derived nanoparticle comprising a first lipid bilayer and a second lipid bilayer coating the exosome-like nanoparticle and/or fused with the first lipid bilayer, wherein the second lipid bilayer comprises a targeting molecule, and methods for using the compositions to treat diseases, disorders, and conditions and/or to target a therapeutic agent to a cell, tissue, and/or organ of interest.
    Type: Application
    Filed: May 24, 2021
    Publication date: June 29, 2023
    Applicant: University of Louisville Research Foundation, Inc.
    Inventor: Huang-Ge Zhang
  • Methods and apparatus for a remote, noninvasive technique to detect core body temperature in a subject via thermal imaging
    Publication number: 20080154138
    Abstract: An approach to noninvasively, remotely and accurately detect core body temperature in a warm-blooded subject, human or animal, via thermal imaging. Preferred features such as the use of in-frame temperature references, specific anatomical target regions and a physiological heat transfer model help the present invention to overcome pitfalls inherent with existing thermal imaging techniques applied to physiological screening applications. This invention provides the ability to noninvasively, remotely and rapidly screen for diseases or conditions that are characterized by changes in core body temperature. One human application of this invention is the remote screening for severe acute respiratory syndrome (SARS), since fever is a common, early symptom. Other diseases and conditions that affect the core body temperature of humans or animals may also be noninvasively and remotely detected with this invention.
    Type: Application
    Filed: February 29, 2008
    Publication date: June 26, 2008
    Inventor: Gary L. McQuilkin
  • PHOTOOXIDATIVE INACTIVATION OF PATHOGENS INCLUDING SARS-CoV-2
    Publication number: 20210346500
    Abstract: Disclosed in certain embodiments is a method of treating a pathogenic infection comprising (i) contacting a pathogen residing in the oral cavity and/or pharynx of a patient in need thereof with a photosensitizer and (ii) subjecting the photosensitizer contacted pathogen to a light source.
    Type: Application
    Filed: May 3, 2021
    Publication date: November 11, 2021
    Inventor: Detlef Schikora
  • TREATMENT FOR SARS-COV-2 AND OTHER CORONAVIRUSES
    Publication number: 20240358798
    Abstract: A method of treating a corona virus infection in a human includes administering to the human an effective amount of at least one a natriuretic peptide (NP) and a neprilysin inhibitor (NI). A pharmaceutical composition for the treatment of corona virus in a human includes one of a recombinant natriuretic peptide (rNP) and a chimeric natriuretic peptide D (CD-NP) and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: July 8, 2024
    Publication date: October 31, 2024
    Inventor: Drora SHEVY
  • Animal Model for SARS-CoV-2-Spike Induced Coagulopathy
    Publication number: 20220184233
    Abstract: Described herein is an animal model useful for identifying therapeutic agents that can inhibit the physiological effects or symptoms of COVID-19 infection, including the effects of the following on one or more organs of the animal: inflammation, oxidative stress, fibrin deposition, blood brain barrier breakdown, clotting, and vascular problems,
    Type: Application
    Filed: December 16, 2021
    Publication date: June 16, 2022
    Inventors: Katerina Akassoglou, Warner Greene, Jae Kyu Ryu, Mauricio Montano
  • SYSTEM FOR IDENTIFYING SEVERE ACUTE RESPIRATORY SYNDROME CORONA VIRUS 2 (SARS-COV-2) RIBONUCLEIC ACID (RNA)
    Publication number: 20210129144
    Abstract: A system for detecting the presence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in a biological sample includes a sampling device, a lysing chamber, a NASBA fluidic network, and an analytical instrument. The sampling device is configured to contain a sample containing a pathogen target sequence for SARS-CoV-2. The lysing chamber is configured to be in fluid communication with the sampling device to receive the sample. The is lysing chamber is configured to lyse the sample into a lysate. The NASBA fluidic network is configured to be in fluid communication with the lysing chamber to receive the lysate. The NASBA fluidic network includes an enzyme, a forward primer, and a reverse primer for amplifying a predetermined genetic sequence in the pathogen target sequence contained within the lysate. The forward primer has the oligonucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 13, and SEQ ID NO: 17.
    Type: Application
    Filed: December 30, 2020
    Publication date: May 6, 2021
    Inventors: Michael BOUCHARD, Steven BRUZEK, Chelsea KNAPP, Lauren McDANIEL, Jessica SMALL, Robert ULRICH, Victoria WAGNER
  • EARLY MANAGEMENT, MITIGATION and PREVENTION OF SEPSIS and SEPSIS-LIKE SYNDROMES, INCLUDING NEO-NATAL ARDS DUE TO INFECTION, INJURY or IATROGENESIS
    Publication number: 20220331291
    Abstract: The present invention relates to the early treatment, including pre-diagnosis treatment, of sepsis and acute inflammatory syndromes such as systemic inflammatory response syndrome (SIRS) by PLA2 and metalloprotease inhibitors to improve the performance of antibiotics and outcomes prior to and after confirmation of the diagnosis of sepsis and/or SIRS in a patient or subject. Additional embodiments include methods of treating sepsis, anthrax and severe acute respiratory syndrome coronavirus (SARS and SARS-CoV2) and related inflammatory syndromes and compositions, including pharmaceutical compositions and blood sample compositions. In further embodiments, the present invention is directed to embodiments which evidence that LY315920, LY333013 and related sPLA2 inhibitors are particularly effective COVID-19/cytokine release syndrome therapeutics-prophylactics.
    Type: Application
    Filed: April 21, 2022
    Publication date: October 20, 2022
    Inventors: Matthew R. Lewin, Rebecca Carter
Narrow Results

Filter by US Classification